PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go:
Extended
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go:
Extended
investment:
£10,000
Sweat IT is a fitness studio in London, which provides supreme high-intensity training experience with the hardest workouts. The UK fitness industry continues to grow high at a value of over £5 billion because of increasing demand for a healthy lifestyle. Sweat IT redefines this with healthy eating and exercise. The company has the vision to take its business growth to the next level and become the leader of boutique fitness. They have partnered with Gympass, the world’s leading corporate fitness platform to deliver high-intensity fitness classes to London based corporate clients. Till date, they have had over 50,000 class bookings with more than 13,000 Instagram followers and a database of 10,000 customers. The company intends on using the investment for marketing and product branding and next-level growth. They are also looking to fund their second studio in London and have ear-marked a potential site in the City.
days to go:
Expired
investment:
£211,220
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
PyroCore is a waste-to-energy technology company. Its technology, Pyrolisis, burns waste and sludge for 30 minutes at 700-900 degree celsius in the absence of oxygen, which leads to reduction of waste volume by 90%, and the energy output can be used for heat, steam or power generation. It also eliminates the need for landfill sites, reduces carbon emissions, and helps businesses cut down on landfill taxes. The company has partnered with institutions such as Brunel University London and The Association for Renewable Energy and Technology. It has also contributed to charities such as Fresh Water Habitats, ALK Positive UK, and others. It is seeking support for deployment of its technology on sites where safe and easy disposal of hazardous or infectious waste can be undertaken, especially in the wake of Covid-19.
days to go:
Expired
investment:
Withheld
Mootral is a British Swiss agro-technology company that has come up with its patented natural feed supplement that significantly reduces methane emissions from ruminants by up to 38%. It claims that cow burps are the single biggest source of methane apart from the oil and gas sector. Mootral argues that its product addresses the above issue. The company teamed up with its flagship UK partner, Brades Farm, to provide them with Mootral for their cattle. Mootral has also earned carbon credits from enteric methane reduction from cattle, averaging >70 € per credit. The company intends to use this to finance the cost of its ruminant and help governments around the world reduce their emission targets. It has also received support from the Swiss Climate Foundation and featured in press entities such as CNN and Sky News. The company states it will use the investment to reach 10% of today's almost 1 billion industrialised cattle by 2030, hire key personnel and develop more climate-friendly solutions.
days to go:
Expired
investment:
£1,868,130
PCL Health is a Business-to-Business (B2B) Software-as-a-Service (SaaS) entity that aims to bring hospital-level care to anyone remotely. It asserts that the correct use of remote monitoring can reduce mortality by up to 45%. PCL Health intends to become a contender in the remote healthcare market that is set to touch $30 billion by 2023. It has developed CE rated medical-grade devices that use health algorithms combined with sensors and its proprietary range of apps to allow family members to proactively monitor the health of their loved ones, alongside carers and doctors, remotely. PCL Health has completed two pilots with 65 people and received a Letter Of Intent (LOI) from a National Health Service (NHS) Trust for a clinical trial. It won the 'Innovative Startup' competition at the 2019 Healthcare Unblocked event. PCL Health will use the investment for technology enhancement, running further pilot studies, and working capital.
days to go:
Expired
investment:
£394,680
